The Journal of Huntington's Disease is a premier academic publication dedicated to advancing the understanding of Huntington's disease and related neurodegenerative disorders. Published by IOS PRESS, this journal has established itself as a vital resource for the scientific community, with an impressive impact factor reflecting its rigorous standards and influential research contributions. With a converged publication period from 2012 to 2024, the journal holds esteemed rankings in the 2023 Q2 category for Cellular and Molecular Neuroscience and Q1 for Neurology (clinical) on Scopus, highlighting its relevance and authority within these critical fields. Researchers, professionals, and students will find a wealth of peer-reviewed articles that examine the molecular mechanisms, clinical manifestations, and therapeutic strategies related to Huntington’s disease. Although not an open-access journal, it provides various access options to ensure that critical research reaches its intended audience. As an essential platform for disseminating groundbreaking findings in neurology and neuroscience, the Journal of Huntington's Disease plays a crucial role in shaping the future of research and treatment strategies related to this devastating condition.

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.

Neurology and Clinical Neuroscience, published by WILEY, is a pivotal peer-reviewed journal dedicated to advancing knowledge in the fields of neurology and clinical neuroscience. With an ISSN of 2049-4173, it encompasses a diverse range of topics related to neurological disorders, offering a platform for groundbreaking research and clinical practices. Although the journal does not currently operate under an open access model, it aims to foster an inclusive academic environment by providing high-quality content that is accessible to both specialists and general practitioners in the medical community. Despite its relatively recent establishment from 2013 to 2024, the journal has gained recognition with Scopus rankings highlighting its role in clinical neurology and neuroscience spheres. It serves as an essential resource for researchers, professionals, and students seeking to expand their understanding and engage in current discussions surrounding neurological health and diseases.

Neurologia i Neurochirurgia Polska is a prestigious Polish journal dedicated to advancements in the fields of neurology and neurosurgery, published by VIA MEDICA. With a rich history dating back to 1967, this journal serves as a critical platform for disseminating significant research findings and clinical practices that advance our understanding of neurological disorders and surgical interventions. Registered under ISSN 0028-3843 and E-ISSN 1897-4260, it boasts commendable rankings as reflected in its 2023 categorical quartiles: Q3 in Neurology (Clinical) and Q2 in Surgery, indicating its substantial impact within these domains. Furthermore, its Scopus rankings reveal that it is positioned at Rank #125/551 within Medicine-Surgery and Rank #187/400 in Medicine-Neurology (Clinical), showcasing its importance in academic and clinical circles. Although not currently open access, the journal remains accessible to readers and practitioners who seek to stay updated on innovative research and methodologies. The journal’s objective is to foster knowledge exchange and stimulate scientific dialogue among researchers, professionals, and students, thus shaping the future of neurology and neurosurgery in Poland and beyond. Located at UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND, it invites contributions that inspire and elevate the standards of medical practice.

Clinical Parkinsonism & Related Disorders is a prominent open-access journal published by Elsevier, focused on advancing the understanding and treatment of Parkinson's disease and related neurological conditions. Since its inception in 2019, this journal has aimed to provide a platform for high-quality research, review articles, and clinical studies dedicated to elucidating the complexities of Parkinsonism and its comorbidities. With an E-ISSN of 2590-1125, it has swiftly established its role in the field of clinical neurology, currently ranked in the Q3 quartile for clinical neurology and Q4 for cellular and molecular neuroscience. While its Scopus rankings reflect a competitive landscape, occupying the 241st position in clinical neurology and the 83rd in neuroscience, the journal remains committed to fostering scholarly dialogue and supporting innovative research. Researchers, clinicians, and students will find valuable insights within its pages, contributing to ongoing discourse and the pursuit of effective therapeutic strategies. Access to all articles has been made available since 2019, emphasizing the journal's mission to disseminate knowledge widely and enhance accessibility in the scientific community.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.